Abstract: A method for controlling condensation of hydrogen peroxide at a preselected temperature within a sealed sterilization chamber including an article to be sterilized includes the steps of applying to the sealed chamber a vacuum of a first pressure sufficient to evaporate, at the preselected temperature, an aqueous solution of hydrogen peroxide of a first concentration. The hydrogen peroxide solution is then evaporated into a water vapor component and a hydrogen peroxide vapor component. The evaporated solution is injected into the sealed chamber in repeated pulses. The injecting is terminated once a preselected second pressure, higher than the first pressure, is reached in the chamber. The pulse volume is selected to allow selective control of the condensation of the hydrogen peroxide vapor component to achieve a layer of micro-condensation of hydrogen peroxide on the article, which layer has a second hydrogen peroxide concentration higher than the first hydrogen peroxide concentration.

Abstract: A wheel motor comprises a stator portion comprising a core secured to an axle and defining air-circulation openings extending through the core, a stator ring mounted about a periphery of the core. The stator ring has teeth separated by slots and windings on the teeth, the windings are connected to a wheel motor controller. A rotor portion comprises an annular case, and structural members rotatably connecting the annular case to the axle, the annular case enclosing permanent magnets opposite the teeth of the stator portion. The structural members define an air-circulation openings extending through the rotor portion. A shielding configuration is between the annular case and an annular surface of the stator portion radially spaced from the axle to define a shielded chamber enclosing the stator ring. The sealed chamber is radially outward of air channels concurrently defined by the air-circulation openings in the stator portion and the rotor portion.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: A method of sterilizing an article by sequentially exposing the article to hydrogen peroxide and ozone is disclosed. The article is exposed under vacuum first to an evaporated aqueous solution of hydrogen peroxide and subsequently to an ozone containing gas. The exposure is carried out without reducing the water vapor content of the sterilization atmosphere, the water vapor content being derived from the aqueous solvent of the hydrogen peroxide solution and from the decomposition of the hydrogen peroxide into water and oxygen. The complete sterilization process is carried out while the chamber remains sealed and without removal of any component of the sterilization atmosphere. For this purpose, the chamber is initially evacuated to a first vacuum pressure sufficient to cause evaporation of the aqueous hydrogen peroxide at the temperature of the chamber atmosphere. The chamber is then sealed for the remainder of the sterilization process and during all sterilant injection cycles.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: Serratia plymuthica strain A30, BCCM Deposit No. LMG P-26170, its analogues or functionally equivalent strains thereto, provides a biological control agent against plant disease caused by a bacterial pathogen, particularly a soft rot, e.g. blackleg. The pathogen is Dickeya spp., Pectobacterium spp., and Ralstonia spp.; including Dickeya sp. biovar 3 strain. The deposited strain and its variants are formulated in an agriculturally or horticulturally acceptable diluent, carrier, filler or adjuvant. Plants or plant parts, particularly potato tubers, containing the deposited strain provide useful propagation material free of soft rot or blackleg disease.